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Abstract
Background: Radical surgical resection of advanced thymic tumors invading either the heart or great vessels facing
towards the heart is uncommonly performed because of the potential morbidity and mortality. To achieve a
complete tumor resection, the use of cardiolpulmonary bypass (CPB) support might be necessary.
Methods: Retrospective analysis of the results in six patients, who underwent radical tumor resection with
CBP support.
Results: Mean age was 46 years (27 to 66 years) and five patients were male. Tumor infiltration of the heart
or the great vessels was evident in all patients. Five patients underwent induction therapy. Two patients were
operated in complete cardioplegic arrest (antegrade cerebral perfusion: n = 1). Arterial cannulation of the ascending
aorta (n = 5) or the femoral artery (n = 1) and venous cannulation of the right atrium (n = 4) or the femoral vein (n = 2)
were performed. Resection of the left brachiocephalic vein (n = 6), resection of the superior caval vein (n = 2), the
ascending aorta (n = 1) and the complete aortic arch with outgoing branches (n = 1) were performed. A macroscopic
complete resection (R0/R1) was achieved in five patients, whereas one patient was resected incompletely (R2).
In-hospital mortality was 0 %. Three (50 %) patients needed operative revision (hematothorax: n = 2, chylothorax: n = 1).
All patients had a complicated postoperative course and developed respiratory insufficiency.
Conclusions: Locally advanced thymoma/thymic carcinoma invading the heart or great vessels can be treated with
radical surgical resection alongside with increased perioperative morbidity. The usage of CBP improves the chance of
complete tumor resection in selected patients and might lead to a prolonged survival.
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Background
Complete surgical resection still builds the mainstay of
treatment in all stages of thymoma and thymic car-
cinoma [1, 2]. Its prognosis depends on the preopera-
tive tumor stage, as classified by the Masaoka-Koga
staging system describing the anatomical extend of
the mediastinal tumor, the World Health Organization
(WHO) histological classification system and the
completeness of surgical resection [3–5]. In particular,
in Masaoka-Koga stage III tumors, defined by the
macroscopic infiltration of neighbouring structures
(i.e., mediastinal pleura, pericardium, lung tissue, and
great vessels), and in stage IVa thymic tumors with
pleural thymoma spread, a complete surgical resection
is not always achievable [6–8]. A multimodality treatment
regime consisting of chemotherapy, surgical resection and
in some cases radiotherapy is recommended for advanced
or primarily unresectable tumors [9, 10].
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However, in this rare surgical condition no common
and standardized treatment regime exists yet and the
optimal way of therapy remains controversial [11, 12].
Most patients presenting with thymoma/thymic car-
cinoma invading the heart or great vessels are not
considered for surgical resection because of technical
reasons, the potential perioperative morbidity and
mortality, and the unknown probability of significant
impact on survival [13]. Therefore, these operative
procedures are uncommonly performed and there
have been only some case reports of patients, who
underwent extended surgical resection with extracor-
poreal circulation in order to achieve complete tumor
resection [14–17]. In this report we describe our ex-
perience of radical surgical tumor resection with car-
diopulmonary bypass (CPB) support in patients with
locally advanced thymoma or thymic carcinoma in-
vading either the heart or great vessels facing towards
the heart.
Methods
This was an observational study. We reviewed the re-
cords of patients with advanced thymoma or thymic
carcinoma, who received surgical resection with CPB
support at the Department of Thoracic Surgery, University
Medical Center Regensburg. Between November 2010
and October 2014 a total of six consecutive patients
with locally advanced thymoma or thymic carcinoma
Masaoka-Koga stage III and IVa with preoperative or
intraoperative evidence of tumor infiltration of the heart,
great vessels, or both, were included. Our Institutional
Review Board waived the necessity of approval for the
data report, because of using only routine patient
data. All patients signed an informed consent form.
Perioperative data and operative reports were ob-
tained from the institutional database and medical re-
cords. Patients were recruited in an interdisciplinary
thoracic oncology assessment involving thoracic sur-
geons, neurologists, oncologists, pulmonary specialists,
radio-oncologists and radiologists. All perioperative
complications regarding postoperative morbidity and
mortality were documented.
All patients received a detailed preoperative history,
physical examination, lung function testing and echo-
cardiography to ensure functional operability. Pre-
operative staging included computed tomography
(CT) scan of the chest in all patients. Cine magnetic
resonance imaging (MRI) was performed to evaluate
the extent of myocardial or great vessel invasion. The
preoperative clinical and pathologic stage at the time
of diagnosis was determined according Masaoka-Koga
staging system [4, 18]. The pathologic results were
classified according to the WHO histological classifi-
cation system [5, 19].
Macroscopic complete surgical resection in a multimod-
ality treatment setting was the aim in all patients. Induc-
tion therapy (chemotherapy or octreotid/prednisone) was
administered in patients with large tumors, which were
considered not completely resectable and in order to
improve surgical resectability (partial remission: tumor
reduction ≥50 %). Second-line treatments were admin-
istered when appropriate depending on tumor stage,
histology and completeness of resection. In addition,
adjuvant therapies were accomplished depending on
the postoperative patient’s status and significant post-
operative comorbidity. A further reason for not per-
forming adjuvant therapy was patient refusal.
Results
Patient characteristics
Patient characteristics and perioperative data are listed
in Table 1. The study comprised six patients who under-
went surgical resection with CPB support of an invasive
thymoma or thymic carcinoma that invaded the myocar-
dium, the superior caval vein (SCV), the left brachioce-
phalic vein (LBV), the ascending aorta and/or the aortic
arch (Figs. 1 and 2). Included were five men and one
woman with a mean age at time of surgery of 46 years
(range 27 to 66 years). There were two patients with
proven myasthenia gravis with one being without symp-
toms since one year before the re-operation due to sus-
picious mediastinal recurrence of thymoma in a time
interval of 26 months after previous transsternal radical
thymoma (WHO type B2) resection.
After clinical and radiological staging the other five
(83 %) patients with first diagnosis of thymoma/thymic
carcinoma received induction therapy with chemother-
apy or octreotid/prednisone. Partial remission was docu-
mented in all patients and surgical resection was the
next step as part of the multimodality treatment con-
cept. Curative resection was the intention to treat in all
patients except one patient with expected tumor debulk-
ing surgery because of suspicious thymoma invasion in
the myocardium of the left ventricle and the main pul-
monary artery.
Operative data
CPB was necessary in all patients to ensure a complete
tumor resection as possible, to relieve the heart for bet-
ter operability and to stabilize the hemodynamics during
preparation. Furthermore, the decision for CPB support
was made intraoperatively for safety reasons and for bet-
ter tumor preparation. Except for one patient (femoral
artery), the ascending aorta was cannulated. The venous
cannulation was performed either in the right atrium
(n = 4) or via the femoral vein (n = 2), depending on
the central tumor invasion in the SCV or the right
atrium. Heparin (350 IE/kg) was administered and
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CPB was performed with mild to moderate hypothermia
(34 to 28 °C), except for one patient in whom hypothermic
circulatory arrest (18 °C) was required for complete recon-
struction of the aortic arch. Cardioplegic cardiac arrest
was necessary in two patients who underwent aortic
surgery.
The surgical procedure was preferably a radical tumor
resection in all patients including the en bloc resection
of the thymoma, along with the thymic gland, perithy-
mic fat tissue, mediastinal pleura, and pericardium.
When appropriate, the resection was extended to the
lungs, phrenic nerves (unilateral) and the chest wall. In
two patients with additional pleural tumor involvement
left-sided radical pleurectomy with resection of the
upper lobe or right-sided extrapleural pneumonectomy
due to distinctive pulmonary tumor infiltration were
performed. Reconstructions of the pericardium or the
diaphragm were performed with bovine patches. The
resected SCV was replaced by a ring-augmented PTFE-
prosthesis (Polytetrafluorethylene; n = 1), whereas the
LBV was either replaced (PTFE-prosthesis: n = 3) or
closed (n = 3). One patient with suspicious mediastinal
thymoma recurrence underwent re-sternotomy and
showed intraoperative tumor infiltration in the as-
cending aorta, which was resected and reconstructed
with a dacron-prosthesis (Hemashield vascular pros-
thesis 28 mm). Final histology ensured only scarred
tissue without evidence of recurrent thymoma. A second
patient had an invasive thymic carcinoma invading the
aortic arch with complete immured supraaortic branches
(Fig. 2). The aortic arch was replaced with a Hemashield
vascular prosthesis (22 mm) under hypothermic circula-
tory arrest (42 min) with selective, antegrade cerebral per-
fusion. Additionally, the brachiocephalic trunk (8 mm),
the left carotid artery (6 mm) and the left subclavian artery
(6 mm) were reconstructed with vascular prostheses
and connected to the aortic arch prosthesis (Fig. 3).
Histological examination confirmed a thymic carcinoma
Table 1 Demographic and perioperative data
Pt Age [years]/
Sex/MG
Masaoka-Koga
[3, 4]/WHO [5]
Induction therapy Cannulation Surgical approach: structures
resected
CPB-/OP-time
[min]
ICU-stay
[days]
1 66/m/none III/A Octreotid/prednisone Ascending aorta/femoral
vein
Sternotomy: SCV, LBV,
pericardium
94/269 28
2 27/m/none IVa (left)/B3 PAC; octreotid/
prednisone
Ascending aorta/RA Sternotomy, left hemi
clamshell thoracotomy: LBV,
pericardium, left pleurectomy,
left upper lobe
152/539 5
3 61/m/none III/C PAC Femoral artery/femoral
vein
Sternotomy: Chest wall, left
upper lobe, pericardium,
LBV, tumor debulking aortic
arch and main pulmonary
artery
378/664 28
4 35/f/MG IVa (right)/B3 PAC; octreotid/
prednisone
Ascending aorta/RA Sternotomy, right hemi
clamshell thoracotomy:
EPP, pericardium, LBV
177/393 13
5 48/m/none III/C PAC Ascending aorta/RA
(hypothermic circulatory
arrest)
Sternotomy: LBV, pericardium,
aortic arch, brachiocephalic
trunk, left carotid artery, left
subclavian artery, wedge
resections right and left lungs
240 (42)/467 26
6 41/m/MG III/B2 None Ascending aorta/RA Sternotomy: LBV, ascending
aorta
121/265 15
CPB cardiopulmonary bypass, EPP extrapleural pneumonectomy, f female, LBV left brachiocephalic vein, m male, MG myasthenia gravis, OP operation, PAC cisplatin,
doxorubicin, cyclophosphamid, Pt patient, RA right atrium, SCV superior caval vein, WHO World Health Organication
Fig. 1 Thymoma Masaoka-stage III (WHO A) with infiltration of SCV
and the right atrium with obstruction. Complete macroscopic
resection (R0) with resection of the SCV and reconstruction with
Dacron-prosthesis under CPB support (cannulation of the ascending
aorta and the femoral vein)
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(WHO type C) with invasion into the aortic wall, the bra-
chiocephalic trunk, left carotid artery and the left sub-
clavian artery, which has been completely resected (R0).
A complete tumor resection (R0) was achieved in four
(66.6 %) patients. A microscopic or macroscopic incom-
plete tumor resection was performed in two patients,
due to tumor infiltration of the aortic arch (R1: n = 1) or
the aortic arch, the main pulmonary artery and the myo-
cardium of the left ventricle (R2: n = 1).
Postoperative data
Postoperative data are shown in Table 2. There was no
in-hospital mortality or death within 30 days after oper-
ation in this series. Severe postoperative complications
requiring soon operative revision were observed in half
of the patients (50 %). Two patients with a hema-
tothorax underwent successful operative revision. On
the third postoperative day, in one patient after extended
reconstruction of the aortic arch left-sided chylothorax
was diagnosed and the patient underwent successful
surgical revision. The postoperative course was pro-
longed and complicated by severe pneumonia with re-
spiratory insufficiency and the need for tracheotomy.
The patient has been discharged in a peripheral hospital
47 days after surgery. We disclaimed postoperative me-
diastinal radiation therapy because of the reduced overall
condition of the patient.
Every patient developed a postoperative respiratory
insufficiency with the need for reintubation with pro-
longed mechanical ventilation followed by tracheot-
omy (n = 5). Despite there was no evidence of
recurrent thymoma and the patient has been free of
symptoms of his myasthenia gravis over one year, the
patient developed in the early postoperative period a
symptomatic myasthenic crisis combined with a pro-
nounced pneumonia of the left lower lobe. The pa-
tient could be successfully treated with intravenous
pyridostigmin and non-invasive ventilation (n = 1).
Postoperative renal insufficiency with temporary renal
replacement therapy was necessary in three (50 %)
patients. The median length of stay on the intensive
care unit (ICU) was 26 days (range: 5 to 28 days). Ex-
cept for one patient (discharge home from hospital
after 31 days) all patients were directly transferred
from the ICU to a peripheral hospital or rehabilita-
tion clinic.
Adjuvant radiotherapy was administered in one patient
with acceptable good postoperative clinical conditions
after R1-resection. In the other patients no further adju-
vant therapy was recommended because of their
impaired clinical overall condition after a prolonged
postoperative course. At the end of the study in June
2015, 83 % (5/6) patients were alive without evidence of
recurrence after a mean follow-up of 20.5 months
(range: 7 to 55 months). One patient died 7 months after
surgery due to further tumor progress after an incom-
plete tumor resection (R2). The functional outcome of
the patients was good.
Fig. 2 CT-scan of patient no. 5 with thymic carcinoma (WHO C) encircling the supraaortic branches and with suspicious invasion of the
aortic arch
Fig. 3 Intraoperative view (patient no. 5) after radical resection of
the thymic carcinoma and vascular reconstruction of the aortic arch
and the outgoing branches
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Discussion
The prognosis of thymoma and thymic carcinoma
depends on resection status, tumor stage, until now
classified by the Masaoka-Koga staging system which de-
scribes the anatomic invasion into surrounding medias-
tinal structures or the pleural cavity, and, at least in
most studies, on WHO-based histology [3–5, 18, 19].
Recently, there is a proposed tumor, node, metastasis
(TNM)-based system, which should be applicable to all
types of thymic epithelial malignancies [20]. In addition,
complete surgical resection is still the most important
determinant of survival in these patients [2, 7, 21, 22].
Especially in patients with advanced thymoma, surgical
resection should be part of a multimodality therapy in-
cluding chemotherapy and in some cases adjuvant radio-
therapy to decrease the risk of recurrence and improve
survival [8, 9, 23–25].
Nevertheless, malignant thymic tumors invading the
heart or great vessels are rarely considered for surgical
resection with curative intention [13]. In the literature
there is only limited data about radical surgical interven-
tions with CPB support presenting only case reports or
case series with small numbers of patients [14–17]. In
our series we describe six patients, who underwent rad-
ical surgical tumor resection with CPB support due to
tumor invasion into the heart or great vessels. All pa-
tients were carefully selected for this aggressive therapy
after multidisciplinary evaluation and proven operability.
Finally, this therapy should be at least considered in pa-
tients who have no further therapeutic alternatives and
only in experienced thoracic surgical centres [13].
Induction therapy is recommended in locally advanced
thymomas not eligible for immediate resection [10]. In
particular, patients presenting with a large, locally
advanced thymoma that is likely to invade adjacent
intrathoracic organs, induction chemotherapy is utilized
to increase resectability with an objective response rate
of approximately 50 % after platin-based combination
chemotherapy [6]. Five (83 %) of our patients received
induction chemotherapy with according to the PAC re-
gime or, if octreotid-positive, with octreotid/prednisone
to ensure better resectability. In all five patients a partial
remission (positive response rate) was observed after re-
evaluation with computed tomography scans. Although,
we only included locally advanced mediastinal tumors
with potential invasion of the heart or great vessels, our
rate of a macroscopic complete resection with removal
of all visible tumor masses was approximately 83 %.
Tumor debulking surgery (R2) was performed in one
patient with massive thymic carcinoma invasion. In our
experience and to our knowledge in the literature, no
curative, complete resection of invasive thymic malig-
nancies is possible, if there is preoperative suspicion or
intraoperative evidence of tumor infiltration in the myo-
cardium of the right/left ventricle. However, this situ-
ation should not primarly be a contraindication for
surgery, because tumor debulking surgery combined
with chemotherapy and radiotherapy is known to im-
prove survival in these patients [1, 12].
Great vessel reconstruction can be performed with
prosthetic material if there is an extensive tumor inva-
sion of the chest wall [13]. The prosthetic graft patency
rates in the left innominate vein position were disap-
pointing (0 %) and in the future we might just ligate the
vein. Complete reconstruction of the aortic arch under
antegrade cerebral perfusion was performed in one pa-
tient (male, 48 years) with an invasive thymic carcinoma
as previously described by Fujino et al. [14].
All of our patients (100 %) developed postoperative
respiratory insufficiency related to pneumonia and also
Table 2 Postoperative and follow-up data
Pt T [20]/UICC Extent of resection/Residual disease Postoperative complications Progress/Recurrence [months] Status/Survivala
[months]
1 3/IIIa R0/none Apoplex, respiratory insufficiency,
tracheotomy
None NED/55
2 4/IIIb R1/aortic arch Pneumonia, respiratory insufficiency,
wound healing disorder
Thymoma metastasis above left
diaphragm, pleural empyema:
complete resection (R0), decortication
NED/20
3 4/IIIb R2/aortic arch, main pulmonary
artery, myocardium
Pneumonia, respiratory insufficiency,
tracheotomy
Mediastinal tumor progress DOD/7
4 3/IIIa R0/none Pneumonia, respiratory insufficiency,
tracheotomy
None NED/25
5 4/IIIb R0/none Pneumonia, respiratory insufficiency,
tracheotomy, gastrointestinal bleeding
None NED/8
6 4/IIIb R0/none Pneumonia, respiratory insufficiency,
myasthenic crisis
None NED/8
UICC Union for International Cancer Control, T T-category, R0 no residual tumor, R1 microscopic residual tumor, R2 macroscopic residual tumor, CT chemotherapy,
RT radiotherapy, NED no evidence of disease, DOD dead of disease
aFollow-up: June 2015
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suffered from a systemic inflammatory response syn-
drome (SIRS). These complications might be triggered
by the usage of the CPB in tumor patients with already
preoperative immunodeficiency related to their malig-
nant disease followed by induction chemotherapy and
extended surgical resections of their malignant tumors.
In addition to the postoperative intensive care treatment,
these patients might benefit from prophylactic, peri-
operative intravenous antibiotic therapy and additional
treatment with immunoglobulines, when appropriate.
Furthermore, thymoma patients could develop postoper-
ative paraneoplastic syndromes including myasthenic
crisis irrespective of their preoperative neurological con-
dition and medication.
Our current overall calculated median survival rate
at the end of the study period in June 2015 was
23 months with five patients being alive without evi-
dence of disease or tumor recurrence. In our depart-
ment, adjuvant radiotherapy is used in patients with
incomplete macroscopic (R2) or microscopic (R1) re-
section and patients with higher histologic thymoma
stages or thymic carcinoma. In this series, only one
patient developed adjuvant radiotherapy.
Finally, to our knowledge and experience, the risk of
systemic dissemination of tumor cells during CPB seems
to be acceptable and lower compared to the risk of
haematogenic tumor cell dissemination caused by the
vessels invasion of the malignant thymoma or thymic
carcinoma.
We are aware of the potential restrictions of our study.
The obvious limitation is its observational nature with
only a small sample size including six patients without
any control group. Nevertheless, we could demonstrate
representative patients with large invasive thymoma or
thymic carcinoma who underwent radical surgical tumor
resection under CPB support.
Conclusions
In conclusion, extensive surgical resections of advanced
thymoma/thymic carcinoma infiltrating the heart or
great vessels with CPB support are technical feasible in
selected patients, but with a significant increased post-
operative morbidity. Great vessel infiltration or infiltra-
tion of the right atrium should not primarily be a
contraindication for surgery. CPB support enables
complete tumor resection in selected patients and might
lead to a better palliation and a potential for cure with
prolonged survival. Surgical resection should always be
performed as part of a multimodality therapy in this se-
lected group of patients and only in experienced thoracic
surgical departments.
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